Boston Scientific's 16% Sales Growth Fails to Impress as Soft Outlook Spooks Investors

Boston Scientific · Earnings · Guidance · Sales

Read More On

Boston Scientific Profit, Sales Rise but Issues Soft Guidancewsj.com

Related Articles

Markets★★Similarity: 69% · Feb 4

Novartis warns investors: Historic patent expiries will slash sales growth and core income

The pharma major said it faces the largest drug-patent expiry headwind in its history this year.

Markets★★Similarity: 69% · Feb 2

AI Demand Propels Teradyne's Q4 Profit to $257.2 Million, Beating Expectations

The company, which makes testing equipment for semiconductors and robotics, posted a fourth-quarter profit of $257.2 million, up from $146.3 million a year earlier.

Tech★★Similarity: 68% · Feb 10

Gilead Sciences delivers strong 2025 earnings, plans new cancer and HIV treatments

The biopharmaceutical company may start to offer two cancer therapies and an additional HIV treatment option this year.

Markets★★Similarity: 68% · Feb 4

GE HealthCare's Q4 Revenue Jumps 7.1%, But Profitability Slips Amid Macro Headwinds

GE HealthCare Technologies said profit fell in the fourth quarter, despite higher revenue, as the company continues to operate in what Chief Executive Peter Arduini called a dynamic macroeconomic environment.